Clinical trial

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

NCT04760431

Study summary

ClinicalTrials.gov

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Taxanes Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tyrosine kinase inhibitor Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-10-01

PhasePHASE2

Conditions

HER2-positive Breast Cancerunresolved

Brain Metastasesunresolved

Interventions

TrastuzumabDRUG · verified · RxNorm: trastuzumab

TaxanesDRUG

PertuzumabDRUG · verified · RxNorm: pertuzumab

Tyrosine kinase inhibitorDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

Peking University International Hospitalcollaborator

Sun Yat-sen Universitycollaborator

Zhejiang Universitycollaborator

Mapped research locations

BeijingBeijing Municipality, China1 GuangzhouGuangdong, China1 HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04760431 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.